Back to search
FDAFDA · Food and drugs·Recall number D-0163-2025

DULoxetine DR USP, 30 mg, 90-count bottle, Rx Only, Packaged by: PD Rx Pharmaceuticals Inc, Oklahoma City, OK 73127, NDC: 43063-877-90

Published January 1, 2025 · Recall initiated: December 4, 2024

Summary

FDA records drug Class II recall D-0163-2025, published January 1, 2025 and initiated December 4, 2024. Recalling firm: PD-Rx Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 70, 90-count bottles; Lot: Lot # I24E77, A24E49, Exp Date: 04/30/25; J23C50, J23C97, L23B39, L23E98, Exp Date: 01/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
PD-Rx Pharmaceuticals, Inc.
Distributor
Distributed within US: FL, MS, WI
Lot
Lot # I24E77, A24E49, Exp Date: 04/30/25; J23C50, J23C97, L23B39, L23E98, Exp Date: 01/31/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was DULoxetine DR USP, 30 mg, 90-count bottle, Rx Only, Packaged by: PD Rx Pharmaceuticals Inc, Oklahoma City, OK 73127, NDC: 43063-877-90 recalled?

Yes. FDA published recall D-0163-2025 on January 1, 2025. Reported hazard: CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail